China Market Intelligence

June 14th, 2017
By David Solomon

Four new policies under development may address a variety of lingering regulatory hurdles for foreign drug and device companies in China. The policies, issued in draft form for comment last month by the China Food and Drug Administration (CFDA), are a step toward improving nationwide access to high-quality drugs and devices, and are part of CFDA’s broader efforts to reform and modernize the Chinese healthcare sector during the 13th Five-Year Plan period.